Normal Saline Versus Hypertonic Saline for Airway STENT Maintenance: SALTY STENT Study.
Journal
Journal of bronchology & interventional pulmonology
ISSN: 1948-8270
Titre abrégé: J Bronchology Interv Pulmonol
Pays: United States
ID NLM: 101496866
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
received:
22
04
2024
accepted:
29
07
2024
medline:
12
9
2024
pubmed:
12
9
2024
entrez:
12
9
2024
Statut:
epublish
Résumé
Mucus plugging is a common complication of airway stenting. There is no data or guidance on the best airway hygiene regimen and consequently wide practice variation exists. This single-center, nonblinded, randomized, pilot study aims to evaluate the effectiveness and safety of nebulized 3% saline (3%S) versus normal saline (NS) in reducing the incidence of mucus plugging in adult patients that undergo central airway stent placement. Patients were enrolled immediately after stent placement and randomized to nebulized 3%S or NS (3 mL) 3 times a day. Patients were scheduled for surveillance bronchoscopy in 4 to 6 weeks. Unscheduled bronchoscopies due to symptomatic mucus plugging were recorded. From December 2022 to March 2024, 37 patients were screened, and 35 were enrolled. Four in the 3%S and 8 in the NS group did not undergo a surveillance bronchoscopy and were excluded from the final analysis. During surveillance bronchoscopy for the 3%S (n=13) and NS (n=10) groups, obstructive mucus plugging was noted in 7.7% versus 40%, granulation requiring intervention in 7.7% versus 10%, and >25% circumferential biofilm in 0% versus 30%, respectively. In the 3%S versus NS groups, 0% versus 20% of patients required an unscheduled bronchoscopy due to mucus plugging. There were no side effects reported with the daily use of 3%S or NS. Nebulized 3%S is safe and may be equally or more effective than NS in preventing obstructive mucus plugging in patients who undergo airway stenting. A larger blinded randomized controlled trial is necessary to confirm this finding.
Sections du résumé
BACKGROUND
BACKGROUND
Mucus plugging is a common complication of airway stenting. There is no data or guidance on the best airway hygiene regimen and consequently wide practice variation exists.
METHODS
METHODS
This single-center, nonblinded, randomized, pilot study aims to evaluate the effectiveness and safety of nebulized 3% saline (3%S) versus normal saline (NS) in reducing the incidence of mucus plugging in adult patients that undergo central airway stent placement. Patients were enrolled immediately after stent placement and randomized to nebulized 3%S or NS (3 mL) 3 times a day. Patients were scheduled for surveillance bronchoscopy in 4 to 6 weeks. Unscheduled bronchoscopies due to symptomatic mucus plugging were recorded.
RESULTS
RESULTS
From December 2022 to March 2024, 37 patients were screened, and 35 were enrolled. Four in the 3%S and 8 in the NS group did not undergo a surveillance bronchoscopy and were excluded from the final analysis. During surveillance bronchoscopy for the 3%S (n=13) and NS (n=10) groups, obstructive mucus plugging was noted in 7.7% versus 40%, granulation requiring intervention in 7.7% versus 10%, and >25% circumferential biofilm in 0% versus 30%, respectively. In the 3%S versus NS groups, 0% versus 20% of patients required an unscheduled bronchoscopy due to mucus plugging. There were no side effects reported with the daily use of 3%S or NS.
CONCLUSION
CONCLUSIONS
Nebulized 3%S is safe and may be equally or more effective than NS in preventing obstructive mucus plugging in patients who undergo airway stenting. A larger blinded randomized controlled trial is necessary to confirm this finding.
Identifiants
pubmed: 39262179
doi: 10.1097/LBR.0000000000000986
pii: 01436970-202410010-00013
pii:
doi:
Substances chimiques
Saline Solution, Hypertonic
0
Saline Solution
0
Sodium Chloride
451W47IQ8X
Types de publication
Journal Article
Randomized Controlled Trial
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: There is no conflict of interest or other disclosures.
Références
Mathew R, Hibare K, Dalar L, et al. Tracheobronchial stent sizing and deployment practices airway stenting practices around the world: a survey study. J Thorac Dis. 2020;12:5495–5504.
Wayne MT, Ali MS, Wakeam E, et al. Current practices in airway stent management: a National Survey of US Practitioners. Respiration. 2023;102:608–612.
Ost DE, Ernst A, Grosu HB, et al. Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life. Chest. 2015;147:1282–1298.
Ortiz-Comino RM, Morales A, Lopez-Lisbona R, et al. Silicone stent versus fully covered metallic stent in malignant central airway stenosis. Ann Thorac Surg. 2021;111:283–289.
Elkins MR, Bye PT. Mechanisms and applications of hypertonic saline. J R Soc Med. 2011;104(suppl 1):S2–S5.
Michon AL, Jumas-Bilak E, Chiron R, et al. Advances toward the elucidation of hypertonic saline effects on Pseudomonas aeruginosa from cystic fibrosis patients. PLoS One. 2014;9:e90164.
Donaldson SH. More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice. Eur Respir J. 2023;62:2300865.
Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–240.
Anuradha K, Gunathilaka PKG, Wickramasinghe VP. Effectiveness of hypertonic saline nebulization in airway clearance in children with non-cystic fibrosis bronchiectasis: a randomized control trial. Pediatr Pulmonol. 2021;56:509–515.
Ralston S, Hill V, Martinez M. Nebulized hypertonic saline without adjunctive bronchodilators for children with bronchiolitis. Pediatrics. 2010;126:e520–e525.
Talamo Guevara M, McColley SA, Rychlik K, et al. Tolerance of 7% hypertonic saline in pediatric cystic fibrosis patients. Pediatr Allergy Immunol Pulmonol. 2020;33:63–68.
Wahidi MM, Lamb CR, Kovitz K, et al. Interventional pulmonology productivity, compensation, and practice benchmarks: the AABIP 2022 Report. J Bronchology Interv Pulmonol. 2023;30:129–134.
Lee HJ, Labaki W, Yu DH, et al. Airway stent complications: the role of follow-up bronchoscopy as a surveillance method. J Thorac Dis. 2017;9:4651–4659.
Matsuo T, Colt HG. Evidence against routine scheduling of surveillance bronchoscopy after stent insertion. Chest. 2000;118:1455–1459.
Ohar JA, Donohue JF, Spangenthal S. The role of Guaifenesin in the management of chronic mucus hypersecretion associated with stable chronic bronchitis: a comprehensive review. Chronic Obstr Pulm Dis. 2019;6:341–349.